Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Multi-center Phase II Trial to Evaluate the Efficacy and Safety of the Combination of HL-085 and Vemurafenib in Advanced Melanoma Patients With BRAF V600E/K Mutation

NCT05263453 is registered in ClinicalTrials.gov with Shanghai Kechow Pharma, Inc. as lead sponsor.

NCT NCT05263453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05263453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Multi-center Phase II Trial to Evaluate the Efficacy and Safety of the Combination of HL-085 and Vemurafenib in Advanced Melanoma Patients With BRAF V600E/K Mutation
Lead sponsor
Shanghai Kechow Pharma, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
September 6, 2021
Completion date
December 31, 2024
Enrollment
104 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma